Stocks and Investing Stocks and Investing
Wed, August 23, 2023

Graig Suvannavejh Reiterated (BTAI) at Hold and Held Target at $4 on, Aug 23rd, 2023


Published on 2024-10-28 06:04:24 - WOPRAI, Graig Suvannavejh
  Print publication without navigation


Graig Suvannavejh of Mizuho, Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Hold and Held Target at $4 on, Aug 23rd, 2023.

Graig has made no other calls on BTAI in the last 4 months.



There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 2 agree with Graig's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, August 15th, 2023
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023


These are the ratings of the 3 analyists that currently disagree with Graig


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $11 on, Friday, August 18th, 2023
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $31 on, Tuesday, August 15th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, August 15th, 2023

Contributing Sources